Cargando…

Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction

Background: The impact of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in addition to optimal medical therapy (OMT) on the right ventricular (RV) systolic function using advanced echocardiographic analysis among outpatients with heart failure and a reduced ejection fraction (HFrEF) has thus f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mustapic, Ivona, Bakovic, Darija, Susilovic Grabovac, Zora, Borovac, Josip A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820989/ https://www.ncbi.nlm.nih.gov/pubmed/36614843 http://dx.doi.org/10.3390/jcm12010042

Ejemplares similares

Left Ventricular Systolic Function After 3 Months of SGLT2 Inhibitor Therapy in Heart Failure Patients with Reduced Ejection Fraction
por: Mustapic, Ivona, et al.
Publicado: (2023)

Right Ventricular Free Wall Strain and Congestive Hepatopathy in Patients with Acute Worsening of Chronic Heart Failure: A CATSTAT-HF Echo Substudy
por: Borovac, Josip A., et al.
Publicado: (2020)

Catestatin in Acutely Decompensated Heart Failure Patients: Insights from the CATSTAT-HF Study
por: Borovac, Josip A., et al.
Publicado: (2019)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT‐HF study
por: Borovac, Josip A., et al.
Publicado: (2020)

Association of inflammatory biomarkers and disease activity with subclinical myocardial dysfunction in psoriatic arthritis
por: Pletikosic, Ivan, et al.
Publicado: (2023)

Improvement in Left and Right Ventricular Function after Introduction of SGLT2 Inhibitors in Heart Failure Outpatients with Reduced Ejection Fraction
por: Alcidi, Gianmarco, et al.
Publicado: (2023)

Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022)

Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
por: Clemmer, John S., et al.
Publicado: (2023)

Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
por: Heath, Rebecca, et al.
Publicado: (2022)

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
por: Pabel, Steffen, et al.
Publicado: (2021)

Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
por: D’Amario, Domenico, et al.
Publicado: (2019)

EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction
por: Wagdy, Kerolos, et al.
Publicado: (2021)

Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
por: De Lorenzi, Andrea Beatriz, et al.
Publicado: (2023)

Right Ventricular Dimension for Heart Failure With Preserved Ejection Fraction Involving Right Ventricular-Vascular Uncoupling
por: Nakagawa, Akito, et al.
Publicado: (2022)

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
por: Nassif, Michael E., et al.
Publicado: (2021)

Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction
por: Kim, Hyue Mee, et al.
Publicado: (2021)

Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension
por: Patel, Ravi B., et al.
Publicado: (2020)

Prevalence of right ventricular dysfunction and prognostic significance in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2020)

SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study
por: Lu, He, et al.
Publicado: (2023)

Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
por: Zhang, Xinxin, et al.
Publicado: (2021)

Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction
por: Guazzi, Marco, et al.
Publicado: (2021)

Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
por: Jiang, Yaohui, et al.
Publicado: (2021)

Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review
por: Jhalani, Nisha B.
Publicado: (2022)

Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular Performance
por: Goliasch, Georg, et al.
Publicado: (2015)

The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction
por: Genuardi, Michael V., et al.
Publicado: (2021)

Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction
por: Yoshihisa, Akiomi, et al.
Publicado: (2020)

Diastolic Ventricular Interaction in Heart Failure With Preserved Ejection Fraction
por: Parasuraman, Sathish K., et al.
Publicado: (2019)

Efficacy of sacubitril‐valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and meta‐analysis
por: Mo, Xingchun, et al.
Publicado: (2023)

SGLT2 inhibitors among patients with heart failure with preserved ejection fraction: A meta-analysis of randomised controlled trials
por: Jaiswal, Akash, et al.
Publicado: (2023)

Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction
por: Nonin, Shinichi, et al.
Publicado: (2018)

Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction
por: Masarone, Daniele, et al.
Publicado: (2020)

Assessment of right ventricular systolic function in heart failure with preserved, reduced and mid-range ejection fraction
por: Mostafa, Shaimaa
Publicado: (2019)

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Forgotten No More—The Role of Right Ventricular Dysfunction in Heart Failure with Reduced Ejection Fraction: An Echocardiographic Perspective
por: Vijiiac, Aura, et al.
Publicado: (2021)

Fibrosis‐4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction
por: Nakashima, Mitsutaka, et al.
Publicado: (2021)

Predictors and prognosis of right ventricular function in pulmonary hypertension due to heart failure with reduced ejection fraction
por: Schmeißer, Alexander, et al.
Publicado: (2021)

Left ventricular volume regulation in heart failure with preserved ejection fraction
por: Kerkhof, Peter L M, et al.
Publicado: (2013)

Left ventricular volume regulation in heart failure with preserved ejection fraction
por: Kerkhof, Peter L M, et al.
Publicado: (2013)

Update of treatment of heart failure with reduction of left ventricular ejection fraction
por: Aronow, Wilbert S.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_i9i519q234066f4ik44e4b6tb0